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Abstract
Objectives The purpose of the present study was to analyze treatment outcome with a full-occlusion biofeedback (BFB) splint on
sleep bruxism (SB) and TMD pain compared with treatment with an adjusted occlusal splint (AOS).
Materials and methods Forty-one patients were randomly allocated to a test (BFB) or a control (AOS) group and monitored over
a 3-month period. Output variables were frequency and duration of bruxing events (bursts) and various pain symptoms.
Results The BFB group showed a statistically significant reduction in the frequency and duration of bursts and a statistically
significant improvement in the patients’ global well-being and the facial muscle pain parameter. After the treatment was stopped,
the BFB group showed a statistically significant reduction in the average and maximum duration but no statistically significant
change in the frequency of bursts.
Conclusions The tested BFB splint is highly effective in reducing SB at the subconscious level, i.e., without waking the patient,
and in achieving improvements in global pain perception. The results suggest that the BFB splint also provides a better treatment
option for bruxism-related pain than an AOS. However, further research is needed, and specifically studies with a larger patient
population displaying higher levels of pain at baseline.
Clinical relevance By reducing burst duration and therefore the pathological load on the masticatory apparatus, the BFB splint
reduces TMD and bruxism-related symptoms and improves patients’ physical well-being. In the long term, this could prevent
damage to the TMJ. This study confirms the effectiveness and safety of this splint.
The universal trial number U1111-1239-2450
DRKS-ID registration DRKS00018092
Keywords Biofeedback/therapy . Occlusal splint . Sleep bruxism/therapy . Vibration . Temporomandibular disorders
Introduction
International bruxism experts have consensually defined
bruxism as “a repetitive jaw muscle activity characterized
by clenching or grinding of the teeth and/or by bracing or
thrusting of the mandible” [1]. The American Academy of
Sleep Medicine (AASM) has categorized sleep bruxism as
“a sleep-related movement disorder” and defines it as “a
stereotyped movement disorder characterized by grinding
or clenching of the teeth during sleep” [2]. Bruxism has
two distinct circadian manifestations: it can occur during
sleep (indicated as sleep bruxism, SB) or during wakeful-
ness (indicated as awake bruxism, AB) [1].
Several studies have demonstrated that bruxism might be a
causal factor of various pain symptoms and functional limita-
tions [3, 4] and a causal factor, or at least a risk factor, in TMD
[5]. Still, the true relationship between these conditions and
bruxism remains uncertain [4].
It is generally accepted that bruxism occurs at a parafunctional
level and entails significant discomfort or damage to affected
patients. A significant proportion of the population is affected
[6]. The search for effective treatments is therefore an essential
objective of scientific research.
Varying statistics have been presented regarding the prev-
alence of bruxism in the general population. This variation is
largely due to the highly divergent experimental setups of
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investigations engaged with the subject. It has been reported
that between 8% and 8.6% of adults exhibit “frequent” brux-
ism and 31.4% exhibit “some” bruxism, irrespective of its
frequency [4, 7–9].
Biofeedback (BFB) has been described as a technique
that provides individuals with information about the con-
dition or activities of their bodies, with the intention of
promoting changes in behavior that result in improved
health or performance [10, 11]. The objective is to make
the subjects aware of harmful processes, enabling a
countervailing response to avoid the undesired effect.
The method is mostly used in the waking state. As the
neurological mechanisms related to AB differ from those
of SB [7], unconscious grinding and clenching while
sleeping cannot be actively inhibited by individual will-
power. It may, however, be possible for subjects to learn
to react to biofeedback even while sleeping [12].
Numerous studies have been conducted on bruxism-
related symptoms, its management, and the effect of
biofeedback on SB. Reviews frequently mention study
limitations and, hence, reasons to call for further re-
search, including small sample sizes, a lack of random-
ization, inadequacies in blinding methodologies, con-
cealment of allocation, handling of withdrawals and
losses, selective or incomplete reporting, short test pe-
riods, the absence of a control group, a lack of adequate
baseline data, and shortcomings in outcome reporting
[13–17].
There may be many reasons why studies would re-
port different results, some of them related to study
design. However, even within a given study, different
results have been reported for different forms of bio-
feedback [13]. This would suggest that we cannot as-
sume that all forms of biofeedback will have the same
effect. The many different approaches make it difficult
to draw definitive conclusions [18]. Whatever new type
of biofeedback treatment becomes available should
therefore invariably be the subject of critical evaluation.
Most accessible studies dealing with the effect of
biofeedback on bruxism have measured muscular (m.
temporalis and/or m. masseter) activity using external
electrodes linked to an electromyograph, with the bio-
feedback stimulus being delivered externally, e.g., using
speakers or supracutaneous electrical impulses [17].
Through the incorporation of a pressure sensor and mi-
crocontroller, the tested splint can be used to measure
bruxing events during sleep. A device using a similar
activation/deactivation system in an occlusal splint was
assessed by other researchers and validated against electro-
myograph (EMG) measurements. It was established that
the operating principle of the tested splint is valid [19].
Unlike previous treatment modes, the present approach en-
tails a dental splint incorporating a vibratory stimulus with an
additional auditory alarm. This is supposed to have several
relevant implications:
& The occlusal splint by itself may influence the treatment.
& The biofeedback is triggered directly by the occlusal force
applied, not indirectly by the measurement of muscular
activity.
& The delivery of the biofeedback stimuli is intrabuccal, i.e.,
delivered at the time and location of the targeted activity.
A pilot study by Gu et al. [20] tested a dental splint
with extrabuccal biofeedback and reported a significant
reduction in the frequency and duration of bruxing
events, but did not assess the effect on the level of
pain. Hara et al. [14] tested an occlusal splint with
intrabuccal biofeedback and reported a reduction in SB
frequency, but did not examine the duration of bruxing
events. The authors reported that there was no signifi-
cant impact on the level of pain.
The present study attempts to evaluate a recently in-
troduced new biofeedback treatment using a larger sam-
ple, comprehensive data collection of a larger number of
outcome variables, and a longer observation period.
Despite the emergence of new therapies, the most
prevalent treatment for bruxism remains the adjusted
acrylic occlusal splint (AOS). This applies to Germany
[21] as well as to other countries [16, 22, 23]. The
literature, however, shows ambivalent results concerning
its effectiveness [24].
In this context, the objective of this study was to test the
following hypotheses:
#1. Treatment with the biofeedback splint reduces the num-
ber and duration of bruxing events.
#2. Treatment with the biofeedback splint leads to a signif-
icantly better improvement in symptoms compared with
the control group (AOS group).
#3. The post-treatment impact of the biofeedback is higher
than in the AOS group.
An additional objective was to monitor for any adverse




Patients older than 18 years displaying TMD and signs of
bruxism who sought treatment at the Department of
Prosthetic Dentistry, University Hospital, Ludwig
Maximilian University of Munich, Germany were recruited.
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Recruitment and follow-up assessment took place from
February 2016 to July 2018.
Inclusion criteria
(1) Physical signs of bruxism visible on the dentition (grind-
ing facets, abnormal tooth wear, or wedge-shaped
lesions)
(2) Self-reported pain in the masticatory muscles or the tem-
poromandibular joint (TMJ)
(3) Willingness of the patient to participate in the study and a
commitment to adhere to the pre-set timetable
(4) Measured SB activity
Exclusion criteria
General medical criteria
(1) Acute pain caused by other components of the mastica-
tory system (e.g., caries, root inflammation)
(2) Prior or planned TMJ or dysgnathia surgery
(3) Jaw fractures
(4) Otorhinolaryngologic diseases (except tinnitus)
(5) Systemic basic illness with rheumatic origin (e.g., arthri-
tis, arthrosis, gout, and psoriasis)
(6) Psychosomatic or psychiatric diseases
(7) Implanted electronic devices
(8) Arrhythmia and other (prior or present) cardiac problems
(9) Epilepsy
(10) Cerebrovascular and brain diseases
(11) Pregnancy including breastfeeding period
(12) Drug or alcohol abuse, analgesic, or sedative therapy,
use of medication affecting the central nervous system
(e.g., antidepressants, anxiolytics, and anticonvulsants)
(13) Physical or mental disability
Criteria specific to the study
(14) Maxillary hyperesthesia or allergy to materials used
(15) Missing support zones in the posterior region
(16) Anatomical topography that made a full-coverage max-
illary splint impossible to use
(17) Anatomical topography that did not tolerate the in-
creased vertical dimension of occlusion
(18) Past history of received biofeedback therapy
(19) Insufficient recorded bruxing activity in the baseline
phase
The above inclusion and exclusion criteria were de-
fined under medically and scientifically meaningful
scrutiny and differ from those stated by the device’s
manufacturer. The manufacturers’ criteria were handed
to each study participant with the device’s manual.
The study environment enabled a higher degree of med-
ical supervision than would normally be available to
patients. Thus, the sample for the study could be drawn
from a slightly broader population. Tooth or jaw mis-
alignments, which would have made it impossible to
produce a functional splint, did not occur.
Following application of the exclusion criteria (see Fig. 1),
a sample of 41 patients formed the trial population.
Insufficient recorded SB activity, medication, and the absence
of compatible computer hardware were the main reasons for
exclusion. All participants were instructed in the use of the
splints and asked to report any use of alcohol or medicines on
their daily control sheets, as these can dampen the response to
biofeedback stimuli.
Three subjects from the AOS group and three subjects from
the BFB group did not complete the test as their biofeedback
splints (in the case of the AOS group subjects, for measure-
ment purposes) developed technical problems. Their data
could be used up to and including phase E2 (see Table 1).
Randomization and blinding
Subjects meeting inclusion criteria were randomly allo-
cated by selection of sealed opaque envelopes to either
of two groups: a control group using a conventional
occlusal splint (AOS group) and a test group using the
biofeedback splint (BFB group). The recruiter had no
information about the allocation pattern. As there were
obvious physical differences between the control and
test splints and it was unavoidable that the patient could
easily identify whether the biofeedback splint was in
applied (i.e., biofeedback mode), patient-side blinding
was not possible.
Because of resource limitations, one member of the univer-
sity staff (a qualified dentist) conducted the study and data
appraisal. There was no therapist-side or analyst-side blinding.
Description of the devices
Maxillary splints were used for both the AOS and BFB
groups. All devices were made by the same technician
in a dental laboratory (Dentaltechnik Michael Seitz,
Munich, Germany). As all splints were manufactured
prior to randomization, a conventional and a biofeed-
back splint were produced for each subject; irrespective
of the group, the subjects were finally allocated to. BFB
splints (with the biofeedback switched off) were needed
for the AOS group as well since they would be worn as
a measuring tool (see the “Study design” section be-
low). The Michigan splints produced for the BFB group
were discarded unused. By manufacturing both splints
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for all subjects prior to randomization, we intended to
remove any possible manufacturing bias and to ensure
adherence to the predetermined timetable.
The BFB splint used in the study differs from the
version the manufacturer sells today. The splint in this
study had a silicone contact tube as sensor (Fig. 2). The
commercial version uses a sensor that is approximately
0.75 mm thinner. From a technical point of view, the
manufacturer has reduced the VDO extension of the
BFB splint.
All AOS and BFB group splints had a flat plane with ho-
mogeneous occlusal contacts in centric relation, with anterior
guidance for excursive moments.
Analog maxillary and mandibular impressions,
interocclusal bite registration, and facial arch transfer/
facebow records (Arcus; KaVo Dental, Biberach, Germany)
were obtained under constant conditions by the same team of
skilled professionals. Plaster casts were manufactured, ana-
lyzed, and mounted in a semiadjustable articulator (KaVo
EWL; KaVo Dental).
Fig. 1 CONSORT flowchart (Word)
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The splint used by the AOS group was made of clear
autopolymerizing dental acrylic resin (Orthocryl;
Dentaurum, Ispringen, Germany) (Fig. 3).
The bruXane splint (bruXane, Marburg, Germany)
used by the BFB group (Fig. 2) was made of two soft
thermoformed full-coverage maxillary dental plates
(bruXflex; Erkodent, Pfalzgrafenweiler, Germany). A
pressure-sensitive sensor was integrated along the entire
occlusal surface, with electronic components housed in
the palatal area, including a rechargeable battery, a vibrat-
ing motor, and a microcontroller.
The microcontroller continuously monitored the resis-
tance level in the sensor. Occlusal pressure on the sensor
reduced the electrical resistance. When the resistance fell
below a predetermined threshold level, the microcontrol-
ler classified this as the start of a bruxing event (burst)
and simultaneously switched on the vibrating motor.
Releasing the occlusal pressure reversed the process,
which the microcontroller recognized as the end of the
burst and stopped the vibrating. The minimum measurable
burst duration was 100 ms; longer bursts were measured
in 100-ms increments.
The threshold for triggering the microcontroller was cali-
brated and documented during production and was equivalent
to 16.1 ± 5.1 kg (mean ± SD) across all subjects. At this level,
normal activities, such as myoclonus, swallowing, or
coughing, would not trigger a response.
Both splints were examined before being handed over
to the patients as well as at each follow-up. The AOS
splints were contoured before being issued to the pa-
tient, initially and at each follow-up if necessary.
Adjustments to the BFB splints were not permitted, so
as to avoid the risk of moisture entering the electronics.
If any unevenness of the occlusal surface was discov-
ered when fitting a splint for a patient, a new bite reg-
istration was taken and sent to the dental laboratory
Fig. 2 Biofeedback splint (BFB) Fig. 3 Adjustable occlusal splint (AOS)





















































































along with the splint for adjustment (if possible) or
remake. No adjustments of the surface of the BFB
splint occurred after data collection had started.
Other researchers have described a device using a
similar activation/deactivation system and validated this
approach against electromyograph (EMG) evidence [25].
Study design
The baseline situation was established as follows:
Bruxing (quantitative) data Both groups wore the biofeed-
back splint in recording-only mode for approximately
2 weeks. A pilot trial showed that the first few nights
would display abnormally low bruxing activity before a
more regular pattern was re-established. As already stat-
ed by Klasser et al., insertion of an unfamiliar object in
the mouth can interrupt the regular bruxing pattern [23].
Therefore, the first four nights´ baseline data were ex-
cluded from the analysis.
Symptoms (qualitative) data The assessment consisted of a
questionnaire survey and a clinical examination according to
the research diagnostic criteria for temporomandibular disor-
ders (RDC/TMD) Axis I and II. The treating dentist was
trained in TMD diagnosis in accordance with the German
version of the RDC/TMD manual [26, 27]. To evaluate a
treatment effect, 4.5 months can be considered appropriate
[28].




Pseudonymized data collection was continual, not just sampled,
i.e., during each phase (measurement phases for the AOS group
and measuring and treatment phases for the BFB group), every
burst during every sleep period was recorded.
The data stored in the microcontroller was periodical-
ly transferred by the subject to a computer as a .csv
file. This file was sent to the Ludwig Maximilian
University of Munich and analyzed using proprietary
software (bruXane, Marburg, Germany), which calculat-
ed the following outcome variables per subject and
sleep period (i.e., per night) from the raw burst data:
Total duration per hour The sum of the durations of each
burst divided by the number of hours of the respective
sleep period, reported in seconds. This is representative
of bruxing activity.
Bursts per hour The number of bursts divided by the number
of hours of the respective sleep period.
Average duration The sum of the durations of each burst di-
vided by the number of bursts in the respective sleep period,
reported in milliseconds.
Maximum duration The duration of the longest individual
burst in the respective sleep period, reported in milliseconds.
Figures 4 and 5 show data for the total duration per hour
(TDPH) for a typical subject (where the subject mean change
Fig. 4 Mean total duration per hour for the AOS group (adjustable occlusal splint), obtained during one night (average subject) (Excel)
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is equivalent to the group mean change) in the AOS and BFB
groups, respectively.
Symptom (qualitative) data
Using questionnaires, the subjects evaluated various spe-
cific pain and functional symptoms on an NRS scale of 0
to 10 at three discrete points in time: immediately before
testing, after 1 month of treatment, and after the second
treatment phase of another 2 months. Additionally, sub-
jects reported on their global pain perception before and
after testing.
Clinical examination
Clinical examinations were undertaken at the time of the ques-
tionnaire surveys. RDC criteria and recommendations were
met and the examination was conducted by the same skilled
professional [26, 27].
Statistical analysis
All data were analyzed with SPSS Statistics 25 (SPSS,
Stanford, CA, USA). The level of significance was set
at p < 0.05. The Kolmogorov-Smirnov test was used to
test the data for normal distribution. Descriptive statis-
tics (means and SD) were calculated. If the assumption
of normality was true, the Student t test was performed.
If it was not, the Wilcoxon signed-rank and Mann-
Whitney U tests were performed.
Non-parametric tests were used for the questionnaire
data. Between groups, the analysis was based on the
pre/post differences within each group. The primary
concern was to analyze each subsequent phase against
the respective baseline (phase T0 or E1, as appropriate).
IMMPACT recommendations
Cognizant of the recommendations of the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) [29], we assessed whether changes
in the patients’ reported symptoms were clinically
meaningful, defined as a change of greater than 30%
in the pre/post mean values.
Results
Demographic data (Table 2)
Fig. 5 Mean total duration per hour for the BFB group (biofeedback splint), obtained during one night (average subject) (Excel)
Table 2 Mean age and gender distribution in the AOS group
(adjustable occlusal splint) and the BFB group (biofeedback splint)
Control Test p
Mean age 41.3 ± 14.2 37.6 ± 11 0.701 (Fisher exact test)
Gender
n 20 19
Female 11 (55%) 10 (52.6%)
Male 9 (45%) 9 (47.4%)
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Baseline phases (T0 and E1)
There was no statistically significant difference between
the AOS and BFB groups at baseline, whether bruxing
(quantitative) data or symptom (qualitative) data. On a
scale of 0 to 10, the mean baseline value for all
symptom/limitation outcomes for both groups was
2.92 ± 1.22.
RDC/TMD Axes I and II
Research diagnostic criteria for temporomandibular dis-
orders (RDC/TMD) were applied to baseline data and
used to detect and classify the diseases of all test sub-
jects. No significant differences were found between the
two groups regarding Axes I and II.
Overview of the measurement and treatment phases
(T0 to T4)
The box plots in Fig. 6 show the nightly total bruxing
duration per hour. The plot on the left shows the total
duration per hour for all three AOS group measurement
phases at baseline (T0), the first follow-up (T2), and the
second follow-up (T4) (see also Table 1). Comparable
measurements during the treatment phases for the AOS
group were not possible due to the study design. There
was considerable variance in each of the phases and
there were similar mean values across all the phases
in the AOS group.
The plot on the right also shows all three measurement
phases (yellow bars) for the BFB group and the two interme-
diate treatment phases (blue bars, T1 and T3) with significant-
ly lower mean values and significantly less variance during
the treatment phases with biofeedback.
Treatment phases (T1 and T3)
Examination of hypothesis #1
Treatment with the biofeedback splint reduces the number of
bruxing events and their duration For each outcome vari-
able, normality of distribution at baseline (T0) and each
of the two treatment phases (T1 and T3) was tested. For
phase T3, data were available for only 17 subjects.
These data were compared with the T0 data for the
same subjects. So T0 (n = 19) was compared with T2
(n = 19) and T0 (n = 17) with T3 (n = 17). The T0 data
Fig. 6 Box plots of the total duration per hour for all phases of the AOS group (adjustable occlusal splint, left) and the BFB group (biofeedback
splint, right) (SPSS)
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were always the same, but in the latter case, they ap-
plied to a subset of the subjects. The results showed
normal distribution for total duration per hour, bursts
per hour (BPF), and average duration (AD). Maximum
duration (MD) showed no normal distribution. A
Student t test was therefore performed for the variable’s
total duration per hour, bursts per hour, and average
duration, while the Wilcoxon signed-rank test for paired
samples was performed for maximum duration.
The results of the statistical tests are given in Table 3.
The table shows the means and standard deviations
for each parameter/phase combination. Statistically
significant reductions (see the p values) were evident
for all outcome variables in the first treatment phase
(T1) within the BFB group. These were maintained or
slightly improved in the second treatment phase (T3).
Evaluation phases (E2 and E3)
Examination of hypothesis #2
Treatment with the biofeedback splint leads to a significant
improvement in patient symptoms compared with the con-
trol group Statistical testing for symptoms and functional
Table 3 Statistical tests for
bruxing activity within the BFB
group (biofeedback splint)
Phase T0 (n = 19)
measurement
T1 (n = 19)
treatment
p value T0 (n = 17)
measurement
T3 (n = 17)
treatment
p value
TDPH (s)a 19.1 ± 16.1 5.2 ± 4.5 0.001 19.6 ± 16.6 4.4 ± 3.5 0.001
BPH (units)a 21.3 ± 14.5 12.9 ± 10.7 0.002 21.3 ± 14.1 12.9 ± 10.0 0.010
AD (ms)a 868.4 ± 315.2 374.8 ± 110.9 < 0.001 879.6 ± 329.8 328.9 ± 94.4 < 0.001
MD (ms)b 11,671 ± 12,839 3526 ± 4407 < 0.001 12,418 ± 13,405 2366 ± 2233 < 0.001
a Student’s paired t test
bWilcoxon signed-rank test













AOS group E2 -6% 10% -33% 18% -11% -43% -41% -26% -21% -17%
AOS group E3 7% 20% 50% 44% 82% -8% -43% -38% 4% -17% -17%
BFB group E2 -35% -17% -33% -24% -43% -13% -27% -58% 17% 44%












Symptom improvement (below the line) & deterioration (above the line)
AOS group E2 AOS group E3 BFB group E2 BFB group E3
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limitations yielded two outcomes for which the BFB group
showed statistically significant improvements over the AOS
group by the end of testing (E3): general pain perception (p =
0.017) and pain in the facial muscles (p = 0.038). There were
no outcomes for which the AOS group performed statistically
better than the BFB group.
Following IMMPACT recommendations [29], Table 4
summarizes the within-group changes in symptom severity
for which either group showed a clinically meaningful
(30%) improvement (below the line) or deterioration (above
the line). Negative percentages indicate a reduction in symp-
tom severity (i.e., an increase in patient well-being) and vice
versa.
For the symptoms most strongly associated with
bruxing (facial muscles, chewing, speaking, and eating),
the biofeedback splint produced meaningfully better re-
sults than the AOS splint.
Measurement phases (T2 and T4)
Examination of hypothesis #3
The post-treatment impact of the biofeedback is larger com-
pared with the control group Comparing the BFB group and
the AOS group produced the following results (green p values
are statistically significant):
Table 5 shows changes in group means and standard
deviations between the phases. Increases in means from
the earlier to the later phase are shown in red. The p-
xvalues are the result of statistical tests on differential
changes between the groups. Total bruxing activity (total
duration per hour) showed a statistically significant im-
provement in the BFB group compared with the AOS
group in phase T2.
The BFB group showed a statistically significant im-
provement in duration of bursts (both average and max-
imum) compared with the AOS group in both post-
baseline measurement phases. No statistically significant
difference was found between the groups in terms of the
frequency of bursts (bursts per hour).
Discussion
Treatment phases (T1 and T3)
Hypothesis #1
Treatment with the biofeedback splint reduces the number of
bruxing events and their durationOn the basis of the data, the
hypothesis is accepted.
There was a statistically significant reduction in total
bruxing activity (total duration per hour) during the treatment
phases with the biofeedback splint compared with baseline
(T0). The second treatment phase (T3) showed few changes
from the first treatment phase (T1), which indicates that the
effect of the biofeedback occurs early and is then sustained.
An extreme illustration of this phenomenon is subject N14
(see Fig. 7).
Of the two components of total duration per hour, both the
frequency (bursts per hour) and average duration (AD) of
bursts significantly declined.
This study did not involve the subjects being woken up by
the biofeedback stimuli. By comparing patients and bed part-
ners´ reports of incidents of being awakened through the bio-
feedback with the number of recorded bruxing events (and,
hence, the presence of biofeedback stimuli), it was found that
the incidence of subjects awaking from the biofeedback was
negligible.
Table 5 Statistical testing for bruxing activity for the AOS group (adjustable occlusal splint) and the BFB group (biofeedback splint)
AOS group BFB group p value AOS group BFB group p value
TDPH 40.1 ± 119.1 (5.1) ± 12.0 0.014 11.5 ± 28.4 (5.2) ± 17.5 0.060
BPH 4.5 ± 16.9 (2.4) ± 9.5 0.281 1.8 ± 11.3 2.2 ± 24.9 0.730
AD 989.8 ± 3.63 (126.5) ±259.6 0.008 283.7 ± 785.2 (189.6) ± 278.7 0.002
MD 24.55 ± 71.94 (2.188) ± 8.77 0.024 12.01 ± 43.74 (5.443) ± 10.27 0.021
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A clinically relevant finding of this study is that the body is
effective in responding to biofeedback at the subconscious
level. It should be noted that the biofeedback was delivered
to the patient directly at the point of the bruxing activity in the
form of two stimuli (vibration and sound), i.e., two senses are
addressed. This is different from the biofeedback applied in
most other studies and may indicate that the type of biofeed-
back system in use may be a relevant factor, i.e., that not all
biofeedback methods have the same effect. Further studies
must be conducted to verify this conclusion.
While the tested biofeedback splint does not measure the
force applied during bruxing, it is likely that longer bursts pro-
duce greater forces (e.g., when comparing the highest recorded
patient mean of 55,445 ms maximum duration with the lowest
recorded patient mean of 1643 ms). Maximum burst duration
could therefore serve as a proxy for measuring the stress on the
stomatognathic system. As shown in Table 3, there was a sig-
nificant reduction in themaximum duration of bursts during the
treatment phases, which could significantly reduce the total
level of stress on the stomatognathic system.
Evaluation phases (E2 and E3)
Hypothesis #2
Treatment with the biofeedback splint leads to a significant
improvement in patient symptoms compared with the con-
trol group The hypothesis is accepted in respect of patients’
global pain perception and pain in the facial muscles. The
AOS showed no statistically significant improvement over
the biofeedback splint regarding any symptoms. No
statistically significant conclusions were drawn in respect of
the other parameters.
The literature suggests that the AOS leads to an improve-
ment in symptoms in the case of TMD and bruxism [16, 23,
30]. Such a conclusion was not confirmed by the results of the
present study.
A limitation of the study was that the number of subjects
reporting specific symptoms was very low in some cases, so
conclusions must be drawn cautiously. For symptom evalua-
tion, unlike the objective measurement of bruxing activity, the
lack of blinding in this study might have biased the outcome
values.
Future studies should focus on subjects displaying more
intense symptoms/functional limitations. The data reveal that
there is a tendency for symptom reduction to be greater when
baseline values are higher and that the reduction is greater, the
longer the therapy phase lasts. Given the inherently subjective
nature of these qualitative tests, the differences within and
between the groups may be more significant when the base-
line level is higher. Furthermore, the disparate performance of
the two treatment methods on different outcome variables
highlights the importance of including a wide range of pain/
functional limitation variables in any research.
Measurement phases (T2 and T4)
Hypothesis #3
The post-treatment impact of the biofeedback is higher than
compared with the control groupOn the basis of the data, the
hypothesis is accepted.
Fig. 7 Total duration per hour, BFB group (biofeedback splint) treatment, and recording periods (Excel)
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The reduction in the test group compared with the control
group was statistically significant for the duration of bursts
(both average and maximum). Whereas the test group bursts
per hour were reduced in phase T2, they increased in phase T4.
These differences were not, however, statistically significant.
The question arises to what extent the measurement meth-
od (use of the biofeedback splint in recording-only mode)
could have influenced the results, particularly regarding the
increased activity in the control group. This outlines a practi-
cal limitation of the present study design. Nevertheless, the
post-treatment measurement method was identical between
the groups, and we would expect any measurement bias to
apply equally to the test group and the control group, also
resulting in an increase in post-treatment bruxing activity in
the test group. The fact that the test group showed a reduction
regarding most variables suggests that there was a long-lasting
effect even after the biofeedback treatment was discontinued.
Another possible factor was the differential vertical dimen-
sion of occlusion (VDO) between the two types of splint. For
technical reasons, the VDO for the biofeedback splint—unlike
for the AOS—was at least 6–10 mm. A reduced VDO is
associated with greater wear comfort and reduced muscular
activity [31]. This effect was not tested for, but it could have
influenced the results.
The results should be viewed within the context that there
was an increase in VDO in the AOS group when switching
from the AOS splint to the recording splint in the follow-up
phases (T2 and T4). This may have influenced the results.
Further studies should rely on EMG measurements to avoid
this problem.
The results show that there was a significant reduction in all
bruxing outcomes during biofeedback treatment. The post-
treatment reduction primarily affected the duration of bruxing
events. In the present study, the treatment phases were limited
to 1 month and 2months, respectively. Because biofeedback as a
therapy is a “process of training” [11], where patients have to
“unlearn their behavior” [17], a greater post-treatment impact
may be expected after a longer treatment phase, possibly
outperforming any effect achievable using a “passive” splint.
Further studies should explore the long-term effects of this com-
bination of splint and biofeedback therapy. As part of such a
study, it would be of interest whether there is a correlation be-
tween the length of the bruxing history and the length of the
treatment phase required to obtain lasting post-treatment effects.
In the present study, the post-treatment measurement phase
was limited to 2 weeks immediately following the treatment
phase. Further studies are required to explore the post-
treatment effect regarding long-term effects.
Changes in mandibular position
If the splint therapy caused relaxation and the patients were
initially in a compressive state of the TMJ (centric relation that
positions the mandible further cranially and dorsally), changes
in the mandibular position could have occurred.
The position of the temporomandibular joints was not
examined in the present study, and no imaging tech-
niques were used. Therefore, no statement can be made
about possible changes in compression. In the BFB
group in particular, no adjustment to the splint was un-
dertaken; hence, the position was not changed. Further
studies are necessary to investigate this issue.
Vertical dimension of occlusion
Another issue is whether and how the greater vertical
dimension of occlusion (VDO) could have affected the
recorded bruxing data. The results show that biofeedback
therapy was effective and that both frequency and dura-
tion of bruxing events were reduced. It is possible that a
greater VDO that interferes with the physiologic rest po-
sition could cause greater muscular activity. If that were
the case, one might expect to record higher bruxing ac-
tivity. The reduction in bruxing activity seen in the study
probably understates the biofeedback effect.
No complications arose and no problems were report-
ed by any patient due to the increased VDO. A few
subjects reported increased snoring and sleeping with
their mouth open.
Adverse events
One subject (N6) in the BFB group reported diffuse neu-
ralgic pain in the region of the right maxillary nerve after
three nights of active biofeedback treatment. The subject
wished to be excused from further participation in the
study. This case was registered as the only adverse event
(AE). There were no cases that could be classified either
as serious adverse events (SAEs) or as suspected unex-
pected serious adverse reactions (SUSARs).
Dropouts
As the biofeedback splint was partly used purely for measure-
ment purposes, this led to excessive material wear and ingress
of moisture during the measurement phase without biofeed-
back in six cases. In these cases, subsequent data were exclud-
ed and considered “technical problems”. This operating mode
of the BFB splint is not used commercially and was developed
exclusively for use in studies.
Discussion summary
& The applied biofeedback therapy led to a significant re-
duction in bruxing activity in terms both of frequency and
of duration.
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& Treatment with the biofeedback splint led to a statistically
significant improvement in patients’ pain perception, both
globally and specifically in relation to facial muscles, also
in comparison with the control group. With respect to
other symptoms, the conclusions that could be drawn were
limited by the small number of the data sets.
& The post-treatment impact of the biofeedback phase was a
statistically significant reduction in the duration of bruxing
events. Long-term effects should be investigated.
Conclusion
Bruxing activity
The tested biofeedback splint achieved a statistically signifi-
cant reduction in bruxing activity during the treatment phase,
in terms of the number of events and, especially, their dura-
tion; there were no adverse effects. While this treatment does
not address the underlying cause of the patient’s bruxism, this
appears to be an effective and safe tool within bruxism treat-
ment. The measurement feature of the biofeedback splint may
help identify the causes of the individual patient’s bruxism and
the extent to which the reported symptoms are due to bruxing.
It was also seen that this biofeedback system seems to func-
tion effectively at the subconscious level (i.e., it does not wake
the patient). Furthermore, the results suggest that the biofeedback
splint reduces the bruxism-related level of stress on the
stomatognathic system, potentially preventing other disorders
that result from the application of bruxism-related forces.
Symptoms and functional limitations
The biofeedback splint provides a statistically significant im-
provement in patients’ general well-being compared with the
conventional AOS.
Treatment with the biofeedback splint led to statistically
significant reduced pain in the facial muscles compared with
the control group. The control group showed no statistically
significant improvement over the test group regarding any of
the variables tested.
Due to the limited number of patients who reported indi-
vidual symptoms, further research is needed to validate these
initial findings.
Post-treatment effects
There is evidence that treatment with the biofeedback splint
achieved a statistically significant reduction in the average and
maximum duration of bursts even after treatment was stopped.
Such reduction was not observed for the number of bursts. It
can be hypothesized that few but extended bursts, which
imply the application of greater force, have a more detrimental
effect on the stomatognathic system than more but shorter
bursts. If this is the case, the observed reduction in the duration
of bursts is the more significant factor in terms of patient well-
being.
Conclusion summary
The biofeedback splint seems safe for therapeutic use and offers
significant benefits to patients. Both splints examined protect
the teeth. By reducing burst duration and, hence, the patholog-
ical load on the masticatory system, the biofeedback splint of-
fers additional positive treatment effects in terms of prophylaxis
and in reducing existing bruxism-related symptoms.
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